ClinicalTrials.gg
CompletedNCT04744935Updated Oct 21, 2026Results posted

Optical Coherence Tomography Guided Laser Treatment of Basal Cell Carcinoma

An interventional study of 1064 nm long-pulse Nd:YAG laser in Basal Cell Carcinoma, Superficial Basal Cell Carcinoma and Nodular Basal Cell Carcinoma, sponsored by Christopher Zachary. Completed at 1 site in United States. Open to participants aged 18 Years to 99 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Christopher Zachary · Not applicable, Interventional, and Treatment

How we know

Updated Oct 21, 2026Now CompletedResults posted+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
29
Allocation
Non-randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 171 studies in Carcinoma, Basal Cell with a site in United States — 23 open to participants now, 38 under way, 2 of them phase 3. Carcinoma, Basal Cell · United States.

Enrollment
88th of 139
29 · median 40
Started
2021
with 12 others
No phase
37 of 171
6 open now
Registered
123rd of 171
by date

Among the 171 studies in Carcinoma, Basal Cell with a site in United States, this one is the 88th largest by enrollment of the 139 interventional ones that give a count, is one of 13 that started in 2021, is one of 37 with no phase, and was the 123rd registered.

Carcinoma, Basal Cell

389 studies on the registry are indexed under Carcinoma, Basal Cell; 69 are open to participants now.

Browse Carcinoma, Basal Cell studies →

Open to participants now

23 of the 171 studies in Carcinoma, Basal Cell with a site in United States are open now. Recruiting first, the newest first:

18 more — sign in →

All 23 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 53 Carcinoma, Basal Cell studies recruiting now, 49 (92%) set no upper age limit and none (0%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 171 studies in Carcinoma, Basal Cell with a site in United States, or all of them as a file.
02

Study summary

Optical coherence tomography guided laser treatment of basal cell carcinoma

Read the detailed description

The purpose of this pilot study is to examine the treatment basal cell carcinoma (BCC) with laser technology under the guidance of optical coherence tomography imaging (OCT). The laser modality that we plan to use is the long-pulse Nd:YAG 1064nm laser, which is a non-ablative laser already shown to effectively treat BCC. Laser treatment of BCC has limited precedent in the literature, but the addition of OCT has the opportunity to enhance outcomes by better targeting the treatment and permitting more precise monitoring of clearance. We propose to use OCT imaging to guide the laser treatment to achieve optimal efficacy with minimized side-effects.

03

Conditions studied

  • Basal Cell Carcinoma
  • Superficial Basal Cell Carcinoma
  • Nodular Basal Cell Carcinoma

Browse trials for

Keywords

  • Basal cell carcinoma
  • Superficial basal cell carcinoma
  • Nodular basal cell carcinoma
  • Optical coherence tomography
  • OCT
  • Laser
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ability to understand and carry out subject instructions or be represented by a legally authorized guardian or representative
  • Ages 18 and older
  • Seeks and is scheduled for treatment of a BCC previously confirmed with

Exclusion criteria

Exclusion Criteria:

Any of the following will exclude participation in the study:

  • Inability to understand and/or carry out instructions
  • Patients with a BCC lesion that requires excision. This would include relatively large lesions (>2.5 cm diameter), lesions that penetrate deep into the skin beyond the depth of the OCT image capture, high risk lesions as defined by the American Academy of Dermatology as recurrent and sclerosing subtype BCC, or .
  • Patients with periocular BCCs which might expose the patient to risk of damage to eyes from the laser.
  • BCCs on legs due to their tendency towards poor wound healing.
  • Pregnancy
  • Patients unable to follow-up for the full 12 months.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
29 participants (actual)

Study arms

  • Active comparator
    Standard

    1064 Long-pulse Nd:YAG laser Fluence: 120 J/cm2 Number of passes: Single Spot size: 2 cm Pulse width: 8-10 msec

    Device: 1064 nm long-pulse Nd:YAG laser

  • Active comparator
    Slow

    1064 Long-pulse Nd:YAG laser Fluence: 20-30 J/cm2 Number of passes: Multiple Spot size: 2 cm Pulse width: 8-10 msec

    Device: 1064 nm long-pulse Nd:YAG laser

Interventions

  • Device1064 nm long-pulse Nd:YAG laser

    BCC lesion will be treated with long-pulse 1064 laser, with surface temperature monitored by infrared camera.

06

What researchers measure

Primary outcomes

  1. Complete Histological Clearance of BCC Lesion

    Those whose lesion is not in a cosmetically sensitive area will undergo a skin biopsy for histological confirmation of OCT results.

    Time frame: 1 year

07

Results

Posted Oct 21, 2026

Participant flow

Participant flow — Overall Study
MilestoneStandardSlow
Started1518
Completed1315
Not completed23
Withdrew: Death01
Withdrew: Lost to follow-up01
Withdrew: Withdrawal by subject21

Outcome measures

PrimaryComplete Histological Clearance of BCC Lesion

Those whose lesion is not in a cosmetically sensitive area will undergo a skin biopsy for histological confirmation of OCT results.

Time frame:
1 year
Reported as:
Count of units · basal cell carcinoma
Complete Histological Clearance of BCC Lesion
basal cell carcinomaStandardSlow
Histological clearance1719
Not histologically cleared32

Adverse events

Collected over 1 year. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Standard0/15 (0%)0/15 (0%)0/15 (0%)
Slow0/18 (0%)0/18 (0%)1/18 (5.6%)
Most frequent other events
Most frequent other events
EventStandardSlow
Pain/itchingSkin and subcutaneous tissue disorders0/151/18

Baseline characteristics

Baseline characteristics were summarized for 41 BCC lesions from 25 unique subjects. Standard included 20 lesions from 13 subjects, and Slow included 21 lesions from 15 subjects; 3 subjects contributed lesions to both protocols. Thus, protocol-level subject counts are not mutually exclusive and may exceed the total number of unique subjects when summed. Age, sex, and race were summarized at the lesion/unit level.

Age, Continuous
Age, Continuous(years)StandardSlowTotal
Mean68.1 ± 11.367.3 ± 9.067.6 ± 9.9
Sex: Female, Male
Sex: Female, Male(basal cell carcinoma)StandardSlowTotal
Female81523
Male12618
Race (NIH/OMB)
Race (NIH/OMB)(basal cell carcinoma)StandardSlowTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White202141
More than one race000
Unknown or Not Reported000
08

Study locations

1 site
  • UCI Health Dermatology Clinic
    Irvine, California 92617, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2021 to primary completion in May 2025, 52 months.

Results were first posted in Oct 2026, 1 year 5 months after primary completion.

Of 50 interventional studies with no phase under Carcinoma, Basal Cell, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 64. This study's 52 months is above that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 21, 2026: primary completion Feb 2027 → May 2025 and completion Feb 2027 → May 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 4, 2021
First posted
Feb 9, 2021
StartActual
Jan 13, 2021
Primary completionActual
May 20, 2025was Feb 2027
CompletionActual
May 20, 2025was Feb 2027
Results first posted
Oct 21, 2026
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 21, 2026
Results
Results posted
posted Oct 21, 2026
Primary completion
Feb 17, 2027→May 20, 2025 (actual)
Oct 21, 2026
Study completion
Feb 17, 2027→May 20, 2025 (actual)
Oct 21, 2026
Enrollment
40 (estimated)→29 (actual)
Oct 21, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedComplete histological clearanceHistological Clearance of BCC lesionLesionTime frame: 1 year
Oct 21, 2026
Documents
Show all 1 update
  1. Oct 21, 2026
    Active, not recruiting→Completed
    Results posted
    Primary completion Feb 17, 2027→May 20, 2025 (now actual)
    Study completion Feb 17, 2027→May 20, 2025 (now actual)
    Enrollment 40 (estimated)→29 (actual)
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedComplete histological clearanceHistological Clearance of BCC lesionLesionTime frame: 1 year
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04744935
Lead sponsor
Christopher Zachary
Responsible party
Christopher Zachary (Professor of the UCI Department of Dermatology, University of California, Irvine) — Sponsor-investigator
First posted
Feb 9, 2021
Start date
Jan 13, 2021
Primary completion
May 20, 2025
Completion
May 20, 2025
Results posted
Oct 21, 2026
Last update
Oct 21, 2026

Study contacts

Christopher Zachary, MBBS FRCP
principal investigator · University of California, Irvine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion